IR@PKUHSC  > 北京大学药学院
学科主题药学
Inhibition of thioredoxin reductase by a novel series of bis-1,2-benzisoselenazol-3(2H)-ones: Organoselenium compounds for cancer therapy
He, Jie1,2; Li, Dongdong3; Xiong, Kun1,2; Ge, Yongjie1,2; Jin, Hongwei1; Zhang, Guozhou1,2; Hong, Mengshi1,2; Tian, Yongliang1,2; Yin, Jin1,2; Zeng, Huihui1,2,3
关键词Organoselenium compound Thioredoxin reductase Anticancer drug Structure-activity relationship
刊名BIOORGANIC & MEDICINAL CHEMISTRY
2012-06-15
DOI10.1016/j.bmc.2012.04.033
20期:12页:3816-3827
收录类别SCI
文章类型Article
WOS标题词Science & Technology
类目[WOS]Biochemistry & Molecular Biology ; Chemistry, Medicinal ; Chemistry, Organic
研究领域[WOS]Biochemistry & Molecular Biology ; Pharmacology & Pharmacy ; Chemistry
关键词[WOS]CELL LUNG-CANCER ; MOTEXAFIN GADOLINIUM ; GROWTH-INHIBITION ; IN-VITRO ; MECHANISM ; SELENOCYSTEINE ; CARCINOMA ; ETHASELEN ; RADIOTHERAPY ; PROGRESSION
英文摘要

Thioredoxin reductase (TrxR) is critical for cellular redox regulation and is involved in tumor proliferation, apoptosis and metastasis. Its C-terminal redox-active center contains a cysteine (Cys497) and a unique selenocysteine (Sec498), which are exposed to solvent and easily accessible. Thus, it is becoming an important target for anticancer drugs. Selective inhibition of TrxR by 1,2-(bis-1,2-benzisoselenazol-3(2H)-one)ethane (4a) prevents proliferation of several cancer cell lines both in vivo and in vitro. Using the structure of 4a as a starting point, a series of novel bis-1,2-benzisoselenazol-3(2H)-ones was designed, prepared and tested to explore the structure-activity relationships (SARs) for this class of inhibitor and to improve their potency. Notably, 1,2-(5,5′-dimethoxybis(1,2-benzisoselenazol-3(2H)-one))ethane (12) was found to be more potent than 4a in both in vitro and in vivo evaluation. Its binding sites were confirmed by biotin-conjugated iodoacetamide assay and a SAR model was generated to guide further structural modification. (C) 2012 Elsevier Ltd. All rights reserved.

语种英语
WOS记录号WOS:000304486500015
项目编号2011M500526
资助机构China Postdoctoral Science Foundation
引用统计
被引频次:36[WOS]   [WOS记录]     [WOS相关记录]
文献类型期刊论文
条目标识符http://ir.bjmu.edu.cn/handle/400002259/60938
专题北京大学药学院
北京大学药学院_天然药物与仿生药物国家重点实验室
作者单位1.Peking Univ, State Key Lab Nat & Biomimet Drugs, Beijing 100191, Peoples R China
2.Peking Univ, Sch Pharmaceut Sci, Beijing 100191, Peoples R China
3.Tianjin Int Joint Acad Biotechnol & Med, Tianjin 300457, Peoples R China
推荐引用方式
GB/T 7714
He, Jie,Li, Dongdong,Xiong, Kun,et al. Inhibition of thioredoxin reductase by a novel series of bis-1,2-benzisoselenazol-3(2H)-ones: Organoselenium compounds for cancer therapy[J]. BIOORGANIC & MEDICINAL CHEMISTRY,2012,20(12):3816-3827.
APA He, Jie.,Li, Dongdong.,Xiong, Kun.,Ge, Yongjie.,Jin, Hongwei.,...&Zeng, Huihui.(2012).Inhibition of thioredoxin reductase by a novel series of bis-1,2-benzisoselenazol-3(2H)-ones: Organoselenium compounds for cancer therapy.BIOORGANIC & MEDICINAL CHEMISTRY,20(12),3816-3827.
MLA He, Jie,et al."Inhibition of thioredoxin reductase by a novel series of bis-1,2-benzisoselenazol-3(2H)-ones: Organoselenium compounds for cancer therapy".BIOORGANIC & MEDICINAL CHEMISTRY 20.12(2012):3816-3827.
条目包含的文件
条目无相关文件。
个性服务
推荐该条目
保存到收藏夹
查看访问统计
导出为Endnote文件
谷歌学术
谷歌学术中相似的文章
[He, Jie]的文章
[Li, Dongdong]的文章
[Xiong, Kun]的文章
百度学术
百度学术中相似的文章
[He, Jie]的文章
[Li, Dongdong]的文章
[Xiong, Kun]的文章
必应学术
必应学术中相似的文章
[He, Jie]的文章
[Li, Dongdong]的文章
[Xiong, Kun]的文章
相关权益政策
暂无数据
收藏/分享
所有评论 (0)
暂无评论
 

除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。